Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Development of pathogenic… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method

Artikel i vetenskaplig tidskrift
Författare John Clemens
Stephen Savarino
Remon Abu-Elyazeed
Mohammad Safwat
Malla Rao
Thomas Wierzba
Ann-Mari Svennerholm
Jan Holmgren
Robert Frenck
Eunsik Park
Abdollah Naficy
Publicerad i J Infect Dis
Volym 189
Nummer/häfte 12
Sidor 2299-307
Publiceringsår 2004
Publicerad vid Institutionen för medicinsk mikrobiologi och immunologi
Sidor 2299-307
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Bacterial Toxins/metabolism, Child, Preschool, Clinical Trials/*methods, Diarrhea/microbiology/prevention & control, Egypt, Enterotoxins/metabolism, Escherichia coli/isolation & purification/metabolism/*pathogenicity, Escherichia coli Infections/microbiology/*prevention & control, *Escherichia coli Proteins, Escherichia coli Vaccines/*administration & dosage/therapeutic use, Evidence-Based Medicine, Feces/microbiology, Fimbriae Proteins/metabolism, Humans, Infant, Research Design, Treatment Outcome, Vaccines, Inactivated/*administration & dosage/therapeutic use
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

BACKGROUND: To design an efficacy trial of a killed oral vaccine against enterotoxigenic Escherichia coli (ETEC) diarrhea in Egyptian children, we derived for ETEC diarrhea an empirical definition that increased the probability that diarrhea associated with excretion of ETEC was caused by the detected ETEC. METHODS: We conducted a cohort study of 397 Egyptian children <24 months old and monitored them until they were 3 years old. Vaccine-preventable (VP) ETEC was defined as ETEC expressing >/=1 of the toxin- (heat-labile [LT] toxin) and colonization-factor antigens (CFA I, II, and IV) in the vaccine. RESULTS: Although fecal excretion of VP-ETEC was highly associated with diarrhea, excretion of LT-ETEC per se was not related to diarrhea (adjusted odds ratio [OR(A)], 1.16 [95% confidence interval [CI], 0.90-1.49]). The fecal excretion of antigenic types of VP-ETEC other than LT-ETEC (non-LT VP-ETEC) was highly associated with diarrheal symptoms (OR(A), 3.91 [95% CI, 2.78-5.49]; P<.001), and this association was greater for nonbloody than for bloody diarrhea. CONCLUSIONS: Because the vaccine had been anticipated to protect primarily against symptomatic ETEC diarrhea, these results indicate that the primary-outcome definition of ETEC diarrhea for the trial should be restricted to nonbloody diarrheal episodes associated with fecal excretion of non-LT VP-ETEC.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?